STOCK TITAN

Castle Biosciences (CSTL) director converts 13,667 RSUs into common shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Castle Biosciences director Miles Harrison exercised Restricted Stock Units into common stock. On May 22, 2026, 13,667 RSUs converted into 13,667 shares of Common Stock at no cash cost, leaving him with 35,631 common shares held directly after the transaction.

Positive

  • None.

Negative

  • None.
Insider Harrison Miles
Role null
Type Security Shares Price Value
Exercise Restricted Stock Units 13,667 $0.00 --
Exercise Common Stock 13,667 $0.00 --
Holdings After Transaction: Restricted Stock Units — 0 shares (Direct, null); Common Stock — 35,631 shares (Direct, null)
Footnotes (1)
  1. Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. The RSUs vest in full on the earlier of the (a) one-year anniversary of the date on May 22, 2026, or (b) the day immediately preceding the next Annual Meeting of Stockholders following the date of the grant.
RSUs exercised 13,667 units Restricted Stock Units converted to common stock on May 22, 2026
Shares received 13,667 shares Common Stock issued upon RSU conversion at $0.0000 per share
Post-transaction holdings 35,631 shares Common Stock held directly after the reported transaction
RSU remaining balance 0 units Restricted Stock Units balance for this award following conversion
Restricted Stock Unit ("RSU") financial
"Each Restricted Stock Unit ("RSU") represents the right to receive one share"
Common Stock financial
"Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock."
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Annual Meeting of Stockholders financial
"the day immediately preceding the next Annual Meeting of Stockholders following the date of the grant."
Exercise or conversion of derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Harrison Miles

(Last)(First)(Middle)
C/O CASTLE BIOSCIENCES, INC.
1500 W. PARKWOOD AVE SUITE 400

(Street)
FRIENDSWOOD TEXAS 77546

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
CASTLE BIOSCIENCES INC [ CSTL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/22/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/22/2026M13,667A(1)35,631D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units(1)05/22/2026M13,667 (2) (2)Common Stock13,667$00D
Explanation of Responses:
1. Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.
2. The RSUs vest in full on the earlier of the (a) one-year anniversary of the date on May 22, 2026, or (b) the day immediately preceding the next Annual Meeting of Stockholders following the date of the grant.
Remarks:
/s/ Frank Stokes, Attorney-in-fact05/27/2025
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did CSTL director Miles Harrison report?

Director Miles Harrison reported exercising Restricted Stock Units into Castle Biosciences common stock. On May 22, 2026, 13,667 RSUs converted into 13,667 common shares, increasing his directly held stake without an open-market purchase or sale.

How many Castle Biosciences (CSTL) shares does Miles Harrison hold after this Form 4?

After the RSU conversion, Miles Harrison holds 35,631 shares of Castle Biosciences common stock directly. These shares reflect his position following the exercise of 13,667 Restricted Stock Units reported in the Form 4 filing.

Was the CSTL Form 4 transaction a market buy or sell of shares?

The Form 4 does not show a market buy or sell. It records an M-code transaction, meaning an exercise or conversion of derivative securities, specifically 13,667 Restricted Stock Units converting into 13,667 common shares at a stated price of zero.

What are Restricted Stock Units (RSUs) in the CSTL Form 4 filing?

Each Restricted Stock Unit represents the right to receive one share of Castle Biosciences common stock. In this filing, 13,667 RSUs were converted into an equal number of common shares, consistent with the footnote describing RSU-to-share conversion mechanics.

What vesting terms are noted for the CSTL Restricted Stock Units?

The filing notes that the RSUs vest in full on the earlier of the one-year anniversary of May 22, 2026, or the day immediately before the next Annual Meeting of Stockholders after the grant date, aligning vesting with time-based and corporate meeting milestones.